• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

A New Innovation for Type 2 Diabetes

By
Clifton Leaf
Clifton Leaf
Down Arrow Button Icon
By
Clifton Leaf
Clifton Leaf
Down Arrow Button Icon
November 17, 2016, 12:34 PM ET

This essay appears in today’s edition of the Fortune Brainstorm Health Daily. Get it delivered straight to your inbox.

It is often the simple fixes (and fixers) that make all the difference in the world: the genius who came up with giving out numbers to deli customers rather than having them mob the counter; assigned seating in movie theaters; E-ZPass.

Indeed, for all the excitement over paradigm-shifting technologies in healthcare and medicine—gene-editing through CRISPR, virtual reality surgical training—it seems we are seeing more and more examples of people solving age-old problems through a stroke of ingenuity. With the proverbial popsicle stick and chewing gum, that is.

And sometimes, the two are combined: a bold new technology is coupled with a strikingly simple, intuitive innovation. That has been my initial impression of a new drug-delivery system, called the Medici, which is made by Intarcia Therapeutics. The Medici is an osmotic pump about the size of a matchstick, which—in a procedure that takes about a minute or so to perform—is inserted under the skin. From there, its makers claim, the pump delivers medicine in a steady-state dose for several months (and even up to a year).

Intarcia has completed several late-stage clinical trials in which it uses the pump to deliver a glucose-controlling drug continuously for months—an idea, that if successful (and approved by the FDA) could significantly help patients with type 2 diabetes, fewer than half of whom maintain the recommended glycemic levels. One big reason why is that it’s often hard to adhere to rigorous schedules for administering medicine.

Intarcia is expected to seek a new drug application for the product from the FDA soon, says Christine Aylward, managing director at Foresite Capital Management, which has backed the company. I’m always leery of writing about medicines and procedures that are still in the experimental stage—so assume all the normal qualifiers and caveats here. But what’s worth noting is that somebody set out in this case not just to make a new drug but to solve a problem that often consumes the lives of diabetes patients. Move over E-ZPass.

About the Author
By Clifton Leaf
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

school
North AmericaEducation
First and second graders born during their pandemic are worse at math and reading
By Moriah Balingit and The Associated PressMarch 10, 2026
21 hours ago
A woman in a red coat holds up a sign that says, “Shouldn’t hurt to be a nurse.”
EconomyLabor
Health care has been propping up a shaky labor market. For the first time in over four years, the sector shed thousands of jobs
By Sasha RogelbergMarch 9, 2026
2 days ago
stitch
Future of WorkSocial Media
‘It feels like a video game, but in real life’: Gen Z’s love of analog ‘grandma’ hobbies jump from Pokemon to bird-watching, scrolling to needlepoint
By Kaitlyn Huamani and The Associated PressMarch 9, 2026
2 days ago
HealthLongevity
From thyroid cancer to 40‑hour fasts: Inside Daymond John’s obsession with biohacking and living longer
By Sydney LakeMarch 8, 2026
3 days ago
AImental health
Chatbots are ‘constantly validating everything’ even when you’re suicidal. New research measures how dangerous AI psychosis really is
By Catherina GioinoMarch 7, 2026
4 days ago
adams
CommentaryVaccines
Trump’s former Surgeon General: voters widely support vaccine access and want Washington to focus elsewhere
By Jerome AdamsMarch 7, 2026
4 days ago

Most Popular

placeholder alt text
Economy
'This cannot be sustainable': The U.S. borrowed $50 billion a week for the past five months, the CBO says
By Eleanor PringleMarch 10, 2026
21 hours ago
placeholder alt text
Real Estate
Billionaires Elon Musk and Mark Zuckerberg used mortgages to buy multimillion-dollar mansions. Here’s why that’s a savvy financial decision
By Sydney LakeMarch 9, 2026
2 days ago
placeholder alt text
Future of Work
Shark Tank's Kevin O'Leary doesn't care if you work from your basement. He just wants to know if you can ‘execute’
By Marco Quiroz-GutierrezMarch 10, 2026
1 day ago
placeholder alt text
Investing
Oracle is under pressure from more than $100 billion in debt and massive layoffs as it pushes ahead with Larry Ellison’s 3-step transformation 
By Amanda GerutMarch 9, 2026
1 day ago
placeholder alt text
Economy
Trump's immigration crackdown is backfiring by hurting the U.S.-born workers it was meant to help, data shows
By Sasha RogelbergMarch 10, 2026
17 hours ago
placeholder alt text
Politics
Washington state wants to keep employers from microchipping workers, before anyone even gets the idea
By Catherina GioinoMarch 10, 2026
16 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.